Search results for "hereditary"

showing 10 items of 650 documents

International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by …

2012

Background There are a limited number of publications on the management of gynecologic/obstetric events in female patients with hereditary angioedema caused by C1 inhibitor deficiency (HAE-C1-INH). Objective We sought to elaborate guidelines for optimizing the management of gynecologic/obstetric events in female patients with HAE-C1-INH. Methods A roundtable discussion took place at the 6th C1 Inhibitor Deficiency Workshop (May 2009, Budapest, Hungary). A review of related literature in English was performed. Results Contraception : Estrogens should be avoided. Barrier methods, intrauterine devices, and progestins can be used. Pregnancy : Attenuated androgens are contraindicated and should …

Complement C1 Inactivator ProteinsAbortionCardiovascularEcallantidechemistry.chemical_compoundDelivery Obstetric; Complement C1 Inactivator Proteins; Humans; Infant Newborn; Breast Neoplasms; Genetic Counseling; Pregnancy; Lactation; Genital Diseases Female; Infant; Contraception; Hereditary Angioedema Types I and II; Menstruation; Pregnancy Complications Cardiovascular; Chemoprevention; Prenatal Diagnosis; Menopause; FemalePregnancyIcatibantPrenatal DiagnosisImmunology and AllergyfertilityHereditary Angioedema Types I and IItreatmentObstetricsVaginal deliveryMenstruationContraceptioncontraceptionGenital DiseasesHereditary angioedemaFemalepregnancyMenopausedeliverymedicine.symptomComplement C1 Inhibitor ProteinDeliverymedicine.drugmedicine.medical_specialtyPregnancy Complications CardiovascularImmunologyBreast NeoplasmsGenetic CounselingIntrauterine deviceChemopreventionbreast cancermedicineHumansLactationGynecologyPregnancygenetic counselingAngioedemabusiness.industryangioedemaInfant NewbornInfantObstetricDelivery ObstetricNewbornmedicine.diseasehereditary angioedemaPregnancy ComplicationsSettore MED/16 - ReumatologiachemistryC1 inhibitor deficiencybusinessGenital Diseases FemaleJournal of Allergy and Clinical Immunology
researchProduct

A fractional-order model for aging materials: An application to concrete

2018

Abstract In this paper, the hereditariness of aging materials is modeled within the framework of fractional calculus of variable order. A relevant application is made for the long-term behavior of concrete, for which the creep function is evaluated with the aid of Model B3. The corresponding relaxation function is derived through the Volterra iterated kernels and a comparison with the numerically-obtained relaxation function of Model B3 is also reported. The proposed fractional hereditary aging model (FHAM) for concretes leads to a relaxation function that fully agrees with the well-established Model B3. Furthermore, the FHAM takes full advantage of the formalism of fractional-order calculu…

Concrete creep020101 civil engineering02 engineering and technologyCondensed Matter Physic0201 civil engineeringRILEM database0203 mechanical engineeringApplied mathematicsGeneral Materials ScienceMechanics of MaterialVariable-order fractional calculuMathematicsMechanical EngineeringApplied MathematicsFractional hereditary aging materialCondensed Matter PhysicsFractional calculusFormalism (philosophy of mathematics)020303 mechanical engineering & transportsFractional aging concreteCreepMechanics of MaterialsIterated functionConcrete relaxationModeling and SimulationMaterials Science (all)Settore ICAR/08 - Scienza Delle Costruzioni
researchProduct

Early and late clinical landmarks of corneal dystrophies

2020

Abstract Corneal dystrophies (CDs) represent a heterogenous group of genetic diseases (Lisch and Weiss, 2019). The International Committee of Classification of Corneal Dystrophies (IC3D) distinguishes between 22 distinct forms of corneal dystrophy (CD) which are predominantly autosomal dominant, although autosomal recessive and X-chromosomal dominant and recessive patterns do exist. A detailed corneal examination of as many affected family members as possible can show the phenotypic differences of the various generations. There are few publications which describe the different CDs with regard to the early and late phenotypes. According to early and late phenotype, three types of CD are gene…

Corneal Dystrophies HereditaryGeneticsTime Factorsgenetic structuresDystrophyCorneal dystrophyLate onsetBiologymedicine.diseasePhenotypeeye diseasesSensory SystemsCorneaCellular and Molecular NeuroscienceOphthalmologyPhenotypeRecessive inheritanceDisease ProgressionmedicineHumanssense organsGeneExperimental Eye Research
researchProduct

The Corneal Dystrophies—Does the Literature Clarify or Confuse?

2018

Corneal Dystrophies Hereditarymedicine.medical_specialtybusiness.industryMEDLINE03 medical and health sciencesOphthalmology0302 clinical medicineInternational Classification of DiseasesTerminology as Topic030221 ophthalmology & optometrymedicineHumansPeriodicals as TopicIntensive care medicineMedical sciencebusiness030217 neurology & neurosurgeryAmerican Journal of Ophthalmology
researchProduct

Nuclear Translocation of Mismatch Repair Proteins MSH2 and MSH6 as a Response of Cells to Alkylating Agents

2000

Mammalian mismatch repair has been implicated in mismatch correction, the prevention of mutagenesis and cancer, and the induction of genotoxicity and apoptosis. Here, we show that treatment of cells specifically with agents inducing O(6)-methylguanine in DNA, such as N-methyl-N'-nitro-N-nitrosoguanidine and N-methyl-N-nitrosourea, elevates the level of MSH2 and MSH6 and increases GT mismatch binding activity in the nucleus. This inducible response occurs immediately after alkylation, is long-lasting and dose-dependent, and results from translocation of the preformed MutSalpha complex (composed of MSH2 and MSH6) from the cytoplasm into the nucleus. It is not caused by an increase in MSH2 gen…

CytoplasmDNA RepairBase Pair MismatchRNA StabilityChromosomal translocationmedicine.disease_causeBiochemistrychemistry.chemical_compoundMismatch Repair Endonuclease PMS2Adenosine TriphosphatasesNuclear ProteinsMethylnitrosoureaNeoplasm ProteinsDNA-Binding ProteinsMutS Homolog 2 ProteinDNA mismatch repairMutL Protein Homolog 1Protein BindingAlkylating AgentsMethylnitronitrosoguanidinecongenital hereditary and neonatal diseases and abnormalitiesGuanineActive Transport Cell NucleusBiologyCell LineO(6)-Methylguanine-DNA MethyltransferaseProto-Oncogene ProteinsDNA Repair ProteinmedicineHumansRNA MessengerneoplasmsMolecular BiologyAdaptor Proteins Signal TransducingCell NucleusMutagenesisnutritional and metabolic diseasesDNACell BiologyDNA MethylationMolecular biologydigestive system diseasesMSH6DNA Repair EnzymesGene Expression RegulationchemistryMSH2Carrier ProteinsGenotoxicityDNADNA DamageHeLa CellsJournal of Biological Chemistry
researchProduct

Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target in LKB1 Mutant Lung Cancer

2013

Abstract The LKB1/STK11 tumor suppressor encodes a serine/threonine kinase, which coordinates cell growth, polarity, motility, and metabolism. In non–small cell lung carcinoma, LKB1 is somatically inactivated in 25% to 30% of cases, often concurrently with activating KRAS mutations. Here, we used an integrative approach to define novel therapeutic targets in KRAS-driven LKB1-mutant lung cancers. High-throughput RNA interference screens in lung cancer cell lines from genetically engineered mouse models driven by activated KRAS with or without coincident Lkb1 deletion led to the identification of Dtymk, encoding deoxythymidylate kinase (DTYMK), which catalyzes dTTP biosynthesis, as synthetica…

DNA Replicationcongenital hereditary and neonatal diseases and abnormalitiesLung NeoplasmsMutantSTK11BiologyAMP-Activated Protein KinasesProtein Serine-Threonine Kinasesmedicine.disease_causeArticleProto-Oncogene Proteins p21(ras)MiceDeoxythymidylate kinaseAMP-Activated Protein Kinase KinasesRNA interferenceCell Line TumorCarcinoma Non-Small-Cell LungmedicineMetabolomicsThymine NucleotidesAnimalsHumansMolecular Targeted TherapyLung cancerskin and connective tissue diseasesCell DeathModels GeneticKinaseCell growthGenomicsmedicine.diseaseMolecular biologyHigh-Throughput Screening AssaysOncologyGene Knockdown TechniquesCancer researchRNA InterferenceKRASNucleoside-Phosphate KinaseDNA Damage
researchProduct

Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema

2002

Danazolmedicine.medical_specialtyHereditary angio-oedemaHepatologyAdenomabusiness.industryHepatocellular adenomamedicine.diseaseGastroenterologyInternal medicineMedicineIn patientbusinessmedicine.drugJournal of Hepatology
researchProduct

Side Effects Of Long-Term Treatment With Danazol And Stanozolol In Hereditary Angioedema

2007

Danazolmedicine.medical_specialtyLong term treatmentbusiness.industryImmunologyHereditary angioedemamedicineImmunology and Allergymedicine.diseasebusinessDermatologyStanozololmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Long-term efficacy of danazol treatment in hereditary angioedema

2010

Background No systematic study has been published yet on the long-term efficacy of attenuated androgens in hereditary angioedema (HAE). Our aim was to conduct a follow-up study in two (German and Hungarian) cohorts of HAE patients (45 and 39 patients, respectively) undergoing uninterrupted treatment for 6 years with similar (starting dose 128 ± 78 mg per day and 136 ± 70 mg per day, respectively) and constant doses of danazol. Design The frequencies of subcutaneous, abdominal and laryngeal attacks were recorded each year. Results The annual frequency of all the three types of attacks was significantly lower during the first year of danazol treatment, compared to the last year before baselin…

Danazolmedicine.medical_specialtybusiness.industryClinical BiochemistryGender distributionGeneral Medicinemedicine.diseaseBiochemistrySurgeryInternal medicineHereditary angioedemaFemale patientCohortmedicineAnalysis of varianceYoung adultAttack frequencybusinessmedicine.drugEuropean Journal of Clinical Investigation
researchProduct

A germline mutation in the platelet-derived growth factor receptor beta gene may be implicated in hereditary progressive mucinous histiocytosis.

2020

DermatologyBiologymedicine.diseaseSkin DiseasesReceptor Platelet-Derived Growth Factor betaHistiocytosisGermline mutationChronic diseaseHereditary progressive mucinous histiocytosisChronic DiseaseCancer researchmedicinePlatelet-Derived Growth Factor Receptor BetaHumansPlatelet-Derived Growth Factor BetaReceptorGeneHistiocytosisGerm-Line Mutation
researchProduct